Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors

Gemcitabine based treatment is currently a standard first line treatment for patients with advanced pancreatic cancer, however overall survival remains poor, and few options are available for patients that fail gemcitabine based therapy. To identify potential molecular targets in gemcitabine refract...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Biol Ther
Egile Nagusiak: Samulitis, Betty K, Pond, Kelvin W, Pond, Erika, Cress, Anne E, Patel, Hitendra, Wisner, Lee, Patel, Charmi, Dorr, Robert T, Landowski, Terry H
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Taylor & Francis 2014
Gaiak:
Research Papers
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4623403/
https://ncbi.nlm.nih.gov/pubmed/25485960
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/15384047.2014.986967
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak